FDA Approves VABYSMO — Genentech, Inc.

# FDA Approves Genentech's VABYSMO for Retinal Disease Treatment Genentech has received FDA approval for VABYSMO (faricimab), a novel intravitreal injection marking the company's entry into the competitive wet age-related macular degeneration and diabetic macular edema markets, where it will compete against established players like Regeneron and Novartis. The approval positions Genentech to capture significant market share in the estimated multi-billion-dollar retinal disease therapeutics sector.